Influencing factors of successful eradication of multidrug-resistant Acinetobacter baumannii in the respiratory tract with aerosolized colistin

Biomedical Journal

Volumn 37, Issue 5, 2014, Pages 314-320

  Chen, Yu Mu ^a   Fang, Wen Feng ^a,b,c   Kao, Hsu ^a   Chen, Hung Chen ^a   Tsai, Yuh Chyn ^c   Shen, Lien Shi ^c   Li, Chin Ling ^c   Chang, Huang Chih ^a   Huang, Kuo Tung ^a   Lin, Meng Chih ^a,b,c   Wang, Chin Chou ^a,b,c,d   Chao, Tung Ying ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

acinetobacter baumannii; aerosolized colistin; multidrug resistant

Indexed keywords

COLISTIMETHATE; COLISTIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AEROSOL; AGED; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM CULTURE; CONTROLLED STUDY; DIABETES MELLITUS; ERADICATION THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTI DRUG RESISTANT ACINETOBACTER BAUMANNII; MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII INFECTION; PNEUMONIA; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SPUTUM CULTURE; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ACINETOBACTER INFECTIONS; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTIDRUG RESISTANCE; RESPIRATORY SYSTEM; VERY ELDERLY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; RESPIRATORY SYSTEM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84908618796     PISSN: 23194170     EISSN: None     Source Type: Journal    
DOI: 10.4103/2319-4170.132879     Document Type: Article

References (29)

1. Joshi SG, Litake GM, Niphadkar KB, Ghole VS. Multidrug resistant Acinetobacter baumannii isolates from a teaching hospital. J Infect Chemother 2003;9:187-90
2. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007;5:939-51
3. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-84
4. Urban C, Segal-Maurer S, Rahal JJ. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2003;36:1268-74
5. Wilson SJ, Knipe CJ, Zieger MJ, Gabehart KM, Goodman JE, Volk HM, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control 2004;32:342-4
6. Tseng CC, Liu SF, Wang CC, Tu ML, Chung YH, Lin MC, et al. Impact of clinical severity index, infective pathogens, and initial empiric antibiotic use on hospital mortality in patients with ventilator-Associated pneumonia. Am J Infect Control 2012;40:648-52
7. Kalin G, Alp E, Coskun R, Demiraslan H, Gundogan K, Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-Associated pneumonia: Do we really need this treatment?. J Infect Chemother 2012;18:872-7
8. Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011;31:1257-64
9. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1985;1:865
10. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-6
11. Kuo SC, Lee YT, Yang SP, Chen CP, Chen TL, Hsieh SL, et al. Eradication of multidrug-resistant Acinetobacter baumannii from the respiratory tract with inhaled colistin methanesulfonate: A matched case-control study. Clin Microbiol Infect 2012;18:870-6
12. Perez-Pedrero MJ, Sanchez-Casado M, Rodriguez-Villar S. Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients. Med Intensiva 2011;35:226-31
13. Lin CC, Liu TC, Kuo CF, Liu CP, Lee CM. Aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii pneumonia: Experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 2010;43:323-31
14. Michalopoulos A, Kasiakou SK, Mastora Z, Rellos K, Kapaskelis AM, Falagas ME. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005;9:R53-9.
15. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-Associated pneumonia. Clin Infect Dis 2006;43 Suppl 2:S89-94
16. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009;48:1724-8
17. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007;11:402-6
18. Kwa AL, Loh C, Low JG, Kurup A, Tam VH. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005;41:754-7
19. Michalopoulos A, Fotakis D, Virtzili S, Vletsas C, Raftopoulou S, Mastora Z, et al. Aerosolized colistin as adjunctive treatment of ventilator-Associated pneumonia due to multidrug-resistant Gram-negative bacteria: A prospective study. Respir Med 2008;102:407-12
20. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: International Guidelines for Management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637
21. Shin JA, Chang YS, Kim HJ, Kim SK, Chang J, Ahn CM, et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection. Yonsei Med J 2012;53:974-84
22. Tasbakan MS, Pullukcu H, Sipahi OR, Tasbakan MI, Aydemir S, Bacakoglu F. Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia?. J Chemother 2011;23:345-9
23. Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 2009;63:775-80
24. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-Associated pneumonia: A matched case-control study. Clin Infect Dis 2010;51:1238-44
25. Rajamohan G, Srinivasan VB, Gebreyes WA. Biocide-Tolerant multidrug-resistant Acinetobacter baumannii clinical strains are associated with higher biofilm formation. J Hosp Infect 2009;73:287-9
26. Lee HW, Koh YM, Kim J, Lee JC, Lee YC, Seol SY, et al. Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect 2008;14:49-54
27. Park JY, Kim S, Kim SM, Cha SH, Lim SK, Kim J. Complete genome sequence of multidrug-resistant Acinetobacter baumannii strain 1656-2, which forms sturdy biofilm. J Bacteriol 2011;193:6393-4
28. Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in Diabetes: Pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 2007;23:3-13
29. Vardakas KZ, Siempos II, Falagas ME. Diabetes mellitus as a risk factor for nosocomial pneumonia and associated mortality. Diabet Med 2007;24:1168-71